Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04609579
Recruitment Status : Recruiting
First Posted : October 30, 2020
Last Update Posted : November 23, 2020
Sponsor:
Information provided by (Responsible Party):
Silicon Therapeutics

Brief Summary:

This clinical trial is evaluating a drug called SNX281 given by itself and in combination with pembrolizumab in participants with advanced solid tumors and lymphoma. The main goals of this study are to:

  • Find the recommended dose of SNX281 that can be given to participants safely alone and in combination with pembrolizumab.
  • Learn more about the side effects and safety profile of SNX281 alone and in combination with pembrolizumab
  • Learn more about pharmacological characteristics of SNX281 alone and in combination with pembrolizumab
  • Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Advanced Lymphoma Drug: SNX281 Drug: Pembrolizumab Phase 1

Detailed Description:

SNX281 is a small molecule activator of the Stimulator of Interferon Genes (STING) protein, with good drug-like properties. Activation of STING initiates the innate immune response and enhances the adaptive immune response, which could potentially activate immune responses to tumors and enhance the response to certain immunotherapies.

This study is a phase I, first in human, open-label study of SNX281 conducted in subjects with advanced solid tumors and lymphomas. The study will comprise of two treatment arms: one evaluating SNX281 as a single-agent, and the other evaluating SNX281 in combination with pembrolizumab. Each treatment arm is designed to include a dose escalation phase followed by a dose expansion phase intended to establish the recommended Phase 2 dose (RP2D).

In the dose escalation phase of each treatment arm, successive cohorts of participants will receive increasing doses of SNX281 designed to determine the maximum tolerated dose (MTD), the dose with maximum pharmacologic activity, or the maximum feasible dose, as a single-agent and in combination with pembrolizumab.

The dose expansion phases of each treatment arm will begin following the determination of an MTD or alternative dose of SNX281 in each respective treatment arm. The single-agent treatment arm of SNX281 is planned to evaluate at least 2 expansion cohorts in ovarian cancer and colorectal carcinoma while the combination treatment arm of SNX281 and pembrolizumab is planned to enroll subjects with advanced cancer who have relapsed on or have become refractory to prior immune checkpoint therapy given in an indicated setting.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 128 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open-label of Study SNX281 Given as Monotherapy and in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors and Lymphoma
Actual Study Start Date : November 18, 2020
Estimated Primary Completion Date : March 18, 2024
Estimated Study Completion Date : March 18, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: SNX281 Monotherapy

SNX281 will be administered weekly in Cycle 1 and then once every 3 weeks of each cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 66 participants will take part in this arm of the study.

Subjects enrolled in the dose expansion phase of this arm may be eligible to add pembrolizumab to their SNX281 therapy following identification of the maximum tolerated dose (MTD) or optimal dose of SNX281 in combination with pembrolizumab. Subjects must, in the opinion of the Investigator, have demonstrated tolerance to SNX281 and have experienced sub-optimal response to therapy (i.e., disease stability for 4 cycles or progression on treatment with SNX281 at any time).

Drug: SNX281
SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle (for up to 6 cycles, or until disease progression or unacceptable toxicity occurs). Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm

Experimental: SNX281 in Combination with Pembrolizumab
SNX281 will be administered weekly in Cycle 1 and then once every 3 weeks of each cycle thereafter. Participants will also receive pembrolizumab once every cycle for up to 6 cycles. The combination of SNX281 and pembrolizumab will be given for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 and pembrolizumab (or SNX281 alone) beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 62 participants will take part in this arm of the study.
Drug: SNX281
SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle (for up to 6 cycles, or until disease progression or unacceptable toxicity occurs). Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm

Drug: Pembrolizumab
Pembrolizumab will be administered as an intravenous infusion on Day 8 in Cycle 1 (28-day cycle) and on Day 1 of each 21-day cycle thereafter (for up to 6 cycles, or until disease progression or unacceptable toxicity occurs).
Other Name: Keytruda




Primary Outcome Measures :
  1. Incidence of dose limiting toxicities to determine the maximum tolerated dose (MTD) and Recommended Phase II dose of SNX281 [ Time Frame: Up to 28 Days ]
    Percentage of participants with dose limiting toxicities associated with SNX281 alone or SNX281 combined with Pembrolizumab during the first cycle. Toxicity will be assessed using the NCI CTCAE Version 5.0

  2. Percentage of participants who experience adverse events and serious adverse events to determine safety and tolerability of SNX281 given as a single agent and in combination with pembrolizumab [ Time Frame: Up to 20 weeks ]
    Percentage of participants who experience adverse events and serious adverse events when given SNX281 as a single agent and in combination with pembrolizumab


Secondary Outcome Measures :
  1. Plasma concentration of SNX281 to characterize the pharmacokinetics (PK) parameters of SNX281 given as a single agent and in combination with pembrolizumab [ Time Frame: Up to 20 weeks ]
    Plasma concentration of SNX281 from all participants given as a single agent and in combination with pembrolizumab.

  2. Plasma concentration of biomarker to determine pharmacodynamics (PD) response to SNX281 given as a single agent and in combination with pembrolizumab [ Time Frame: Up to 20 weeks ]
    Plasma concentration of biomarker from all participants receiving SNX281 as a single agent and in combination with pembrolizumab

  3. Objective response rate (ORR) to assess the clinical activity of SNX281 given as a single agent and in combination with pembrolizumab [ Time Frame: Up to 40 months ]

    Proportion of participants with confirmed complete response (CR) or partial response (PR) according to disease specific response criteria

    Per RECIST 1.1: A CR is the complete disappearance of all target and non-target lesions. A PR is a ≥30% decrease in the sum of diameters of target lesions from the baseline sum

    Per RECIL2017:

    A CR is the complete disappearance of all non-target/target lesions/all nodes with long axis <10 mm, or ≥30% decrease in the sum of longest diameters of target lesions (PR) with normalization of FDG-PET and no bone marrow involvement or appearance of new lesion

    A PR is ≥30% decrease in the sum of longest diameters of target lesions, with positive FDG-PET with any bone marrow involvement and no appearance of new lesions and no progression of non-target lesions.


  4. Duration of response (DoR) to assess the clinical activity of SNX281 given as a single agent and in combination with pembrolizumab [ Time Frame: Up to 40 months ]

    Defined as: Time from first documented response (Complete response (CR) or partial response (PR)) to first evidence of progressive disease (PD) per disease-specific response criteria or death due to any cause.

    RECIST 1.1- CR: Disappearance of all target/non-target lesions. PR: ≥30% decrease in the sum of diameters of target lesions from baseline sum. PD: ≥20% increase in target lesions and ≥5mm from smallest sum, any new lesions, or unequivocal progression of non-target lesions.

    RECIL 2017- CR: Disappearance of non-target, target/nodal lesions or ≥30% decrease in the sum of longest diameters of target lesions with normal FDG-PET, no bone marrow (BM) involvement or new lesion. PR: ≥30% decrease in the sum of longest diameters of target lesions but not a CR with any BM involvement but no new lesion or non-target lesions progression.

    PD: New lesion appearance or ≥20% increase in sum of target lesions. If lymph N<15 mm post therapy,a ≥5 mm increase with longest diameter exceeds 15mm


  5. Progression free survival (PFS) to assess the clinical activity of SNX281 given as a single agent and in combination with pembrolizumab [ Time Frame: Up to 40 months ]

    Progression free survival is defined as the time from the first day of study drug administration to disease progression (PD) as defined by disease-specific response criteria (RECIST 1.1 or RECIL2017), or death on study.

    RECIST 1.1:

    PD: ≥20% increase in target lesions sum and ≥5mm from smallest sum, any new lesions, or unequivocal progression of non-target lesions.

    RECIL 2017:

    PD: New lesion appearance or ≥20% increase in sum of longest diameters of target lesions. For lymph nodes measuring <15 mm post therapy, a ≥5 mm increase with longest diameter exceeds 15mm


  6. Overall survival (OS) to assess the clinical activity of SNX281 given as a single agent and in combination with pembrolizumab [ Time Frame: Up to 40 months ]
    Overall survival (OS) is defined as the time from the first day of study drug administration (Day 1) to death

  7. Disease control rate (DCR) to assess the clinical activity of SNX281 given as a single agent and in combination with pembrolizumab [ Time Frame: Up to 40 months ]

    DCR is defined as:The proportion of subjects who achieved either a complete response (CR), partial response (PR), or stable disease (SD)at their first scheduled disease assessment according to disease-specific response criteria

    RECIST 1.1 CR: disappearance of all target/non-target lesions. PR: ≥30% decrease in the sum of diameters of target lesions from baseline sum. SD: Neither sufficient shrinkage to qualify for a PR nor sufficient increase in lesions for a PD

    RECIL2017 CR: Disappearance of all target/nodal lesions or ≥30% decrease in the sum of longest diameters of target lesions with normal FDG-PET and no bone marrow (BM) involvement or new lesion.

    PR: ≥30% decrease in the sum of longest diameters of target lesions with positive FDG-PET with any BM involvement and no new lesion.

    SD: Less than 10% decrease or up to 20% increase in the sum of longest diameter of target lesions with any FDG-PET result or any bone marrow involvement and no appearance of new lesion




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must meet the following criteria in order to be included in the research study:

    1. Written informed consent, according to local guidelines, signed and dated by the subject or by a legal guardian prior to the performance of any study-specific procedures, sampling, or analyses
    2. At least 18 years-of-age at the time of signature of the informed consent form (ICF)
    3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
    4. Histological or cytological requirements as follows:

      a. Dose Escalation: i. All treatment arms: Subjects with histological or cytological documentation of advanced/recurrent solid tumors or lymphoma who have progressed on, are intolerant of, or are ineligible for existing standard therapies

      b. Dose Expansion: i. SNX281 Monotherapy: Subjects with histological or cytological documentation of advanced/recurrent ovarian or colorectal cancer who have progressed on, are intolerant of, or are ineligible for existing standard therapies. Subjects may be checkpoint inhibitor naïve. Subjects who qualify to add pembrolizumab to their treatment regimen, must meet all medical eligibility requirements for receiving pembrolizumab (see Inclusion Criteria 9).

      ii. SNX281 in Combination with Pembrolizumab: Subjects with histological or cytological documentation of advanced/recurrent solid tumors or lymphoma who have relapsed on or are refractory to prior checkpoint inhibitor therapy given in an indicated setting. (Note: recruitment may be stopped in a given anatomical indication if no evidence of clinical response is observed in 15 subjects.)

    5. Measurable or evaluable disease according to disease-specific tumor assessment criteria. Subjects in dose expansion portions of the study must have at least 1 measurable lesion that has not been previously irradiated, or has progressed after prior irradiation.
    6. Adequate organ function, defined as:

      a. Hematologic systems i. Absolute neutrophil count (ANC) ≥1.5 × 109/L ii. Hemoglobin ≥9 g/dL iii. Platelets ≥100 × 109/L

      b. Hepatic system i. Total bilirubin ≤1.5 × the upper limit of normal (ULN) (for subjects with Gilbert's Syndrome ≤3.0 × ULN [if direct bilirubin ≤35%]) ii. Alanine aminotransferase and aspartate aminotransferase ≤2.5 × ULN; and for subjects with liver metastases ≤5.0 × ULN

      c. Renal system i. Estimated glomerular filtration rate (eGFR) by Cockcroft-Gault formula >50 mL/min

      d. Cardiac system i. Ejection fraction ≥50% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan

    7. Male subjects with female partners of childbearing potential and female subjects of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 3 months following the last dose of SNX281 for male subjects and 6 months following the last dose of SNX281 for female subjects, and for 120 days following the last dose of pembrolizumab for all subjects receiving pembrolizumab. Male subjects must also refrain from donating sperm during their participation in the study and for 3 months following the last dose of SNX281 and 120 days after the last dose of pembrolizumab
    8. Life expectancy ≥12 weeks after the start of the treatment according to the Investigator's judgment.
    9. Subjects considered for any combination of pembrolizumab and SNX281 must meet, in the opinion of the Investigator, any additional criteria necessary for the safe and proper use of pembrolizumab.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from study entry:

  1. Malignancy other than the disease under study with the exception of those from which the subject has been disease-free for more than 2 years and not expected to affect the safety of the subject or the endpoints of the trial. Curatively treated non-melanoma skin cancer is permitted.
  2. Symptomatic central nervous system metastases or asymptomatic CNS metastases must be treated and stable for 2 weeks prior to initiation of study treatment. Follow-up scans to confirm stability after 2 weeks are not required. Subjects with carcinomatous meningitis or leptomeningeal spread are excluded regardless of clinical stability.
  3. Active autoimmune disease that has required systemic disease modifying or immunosuppressive treatment within the last 2 years. Replacement therapy (e.g., thyroxine or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, insulin for type 1 diabetes, etc.) is permitted.
  4. Concurrent medical conditions requiring the use of systemic immunosuppressive treatment within 28 days before the first dose of study treatment. Physiologic doses of corticosteroids (not exceeding 10 mg/day prednisone or equivalent) for treatment of endocrinopathies or steroids with minimal systemic absorption, including topical, inhaled, or intranasal corticosteroids may be continued if the subject is on a stable dose.
  5. Current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if subject otherwise meets entry criteria
  6. History of vasculitis at any time prior to study treatment
  7. Evidence or history of significant active bleeding or coagulation disorder
  8. Active infection requiring systematic treatment, known human immunodeficiency virus infection (HIV), or positive test for hepatitis B surface (HBs) antigen or hepatitis C virus (HCV).
  9. QT interval corrected for heart rate according to Fridericia's formula >480 msec by machine read or human over-read. Pre-existing bundle branch block is permitted at the Investigator's discretion.
  10. Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction.
  11. Recent history (within 4 weeks of starting study) of allergen desensitization therapy
  12. History or evidence of cardiovascular risk including any of the following: recent (within the past 6 months) serious uncontrolled cardiac arrhythmia or clinically significant electrocardiogram (ECG) abnormalities including second degree (Type II) or third degree atrioventricular block; cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting, or bypass grafting within the past 6 months before enrollment; congestive heart failure (Class II, III, or IV) as defined by the New York Heart Association functional classification system.
  13. Recent (within the past 6 months) history of symptomatic pericarditis
  14. History of idiopathic pulmonary fibrosis, interstitial lung disease, organizing pneumonia, or current pneumonitis or a history of non-infection pneumonitis that required steroids. Note: post-radiation changes in the lung related to prior radiotherapy and/or asymptomatic radiation-induced pneumonitis not requiring treatment may be permitted if agreed upon by the Investigator and Sponsor
  15. Symptomatic ascites or pleural effusions
  16. Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedures
  17. Prior treatment with the following agents:

    • Systemic stimulator of interferon genes (STING) agonist at any time (prior intra-tumoral STING agonist is acceptable)

      o Subjects treated in Treatment Arm 1 (SNX281 Monotherapy) who experience disease progression (PD) may be allowed to receive pembrolizumab in combination with SNX281 with Sponsor approval

    • Anticancer therapy or investigational therapy within 28 days or 5 half-lives of the drug, whichever is shorter
    • PD-1, PD-L1, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors within 28 days of the start of study treatment (SNX281 Monotherapy treatment arm only)
    • Prior radiation therapy: permissible if at least 1 non-irradiated evaluable lesion is available for assessment according to disease-specific tumor response criteria, or if a solitary evaluable lesion was irradiated, objective progression of that lesion is documented. A washout period of at least 14 days before start of study treatment for radiation of any intended use to the extremities for bone metastases and 28 days for radiation to the chest or visceral organs is required. For radiation to the brain, a washout period of at least 14 days for stereotactic body radiation therapy (SBRT) or stereotactic radiosurgery (SRS) and 28 days for whole brain radiotherapy (WBRT) is required. Palliative radiation is permissible at any other time before or during the study.
    • Strong inhibitors and inducers of CYP3A4 must be discontinued 7 days or for a time equivalent to 5-half-lives of the medication (whichever is longer) prior to initiation of SNX281 treatment.
  18. Receipt of any live vaccine within 30 days of the start of treatment
  19. Prior allogeneic or autologous bone marrow transplantation or other solid organ transplantation
  20. Toxicity from previous treatment including toxicity Grade .3 related to prior immunotherapy and that led to study treatment discontinuation; toxicity related to prior treatment that has not resolved to Grade ≤1 (except alopecia, hearing loss, or Grade ≤2 neuropathy or endocrinopathy managed with replacement therapy).
  21. Received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, and recombinant erythropoietin) within 7 days before the first dose of study treatment.
  22. Major surgery ≤28 days before the first dose of study treatment. Subjects must have also fully recovered from any surgery (major or minor) and/or its complications before initiating treatment. Port-a-cath placement is permitted.
  23. Active drug or alcohol abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04609579


Contacts
Layout table for location contacts
Contact: Humphrey Gardner, Chief Medical Officer, MD, FCAP (781)375-6856 humphrey.gardner@silicontx.com
Contact: Salah Nabhan, MS (479)530-3530 salah.nabhan@silicontx.com

Locations
Layout table for location information
United States, Florida
Florida Cancer Specialist Recruiting
Sarasota, Florida, United States, 34232
Contact: Judy Wang, MD         
United States, Tennessee
Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
Contact: Melissa Johnson, MD         
Sponsors and Collaborators
Silicon Therapeutics
Investigators
Layout table for investigator information
Study Chair: Melissa Johnson, MD SCRI Development Innovations, LLC
Layout table for additonal information
Responsible Party: Silicon Therapeutics
ClinicalTrials.gov Identifier: NCT04609579    
Other Study ID Numbers: SNX281-001
First Posted: October 30, 2020    Key Record Dates
Last Update Posted: November 23, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Silicon Therapeutics:
Stimulator of interferon genes
STING agonist
Ovarian Neoplasms
Colorectal Neoplasms
Microsatellite stable colorectal
Microsatellite instable colorectal
Lymphoma
B-Cell Lymphomas
Solid Tumor
Advanced Tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents